DiamiR, AlzLabs team up to analyze blood biomarkers for Alzheimer’s

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Aptorum Group announced a collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics to generate protein and microRNA blood-based biomarker data focused on Alzheimer’s disease.

The analysis will use well-characterized plasma samples whose amyloid status was determined by amyloid PET and will measure biomarkers including p-Tau 217, amyloid 42/40, neurofilament light (NfL) and other analytes, and will evaluate these panels alone and in combination with DiamiR’s CogniMIR platform.

DiamiR will conduct testing in its CLIA-certified, CAP-accredited laboratory and aims to expand non-invasive brain health biomarker offerings for clinical testing and biopharma services.

The announcement also reiterates that Aptorum and DiamiR entered a definitive merger agreement on 16 July 2025, and that shareholders of both companies approved the merger on 9 June 2026; completion remains subject to customary closing conditions and is expected before fiscal 2027.

Upon closing, DiamiR is slated to become a wholly owned subsidiary and the combined entity will be renamed Niki BioSolutions, Inc., according to the company.

Source: https://www.globenewswire.com/news-release/2026/06/22/3315235/0/en/aptorum-group-announces-collaboration-between-diamir-biosciences-and-alzlabs-precision-diagnostics-for-alzheimer-s-disease-biomarkers.html

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Novartis exits a BioArctic deal worth up to $802m

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE